Thomas Dick, Ph.D., is Member of the Center for Discovery and Innovation and Professor at the Hackensack Meridian School of Medicine at Seton Hall University.
Dr. Dick has 20 years of experience in mycobacteriology and anti-mycobacterial drug discovery. Prior to his current appointments as Member at the Center for Discovery and Innovation, Hackensack Meridian Health (CDI) and Professor at Hackensack Meridian School of Medicine and Georgetown University, he was Tuberculosis (TB) disease area head at Novartis and served as Associate Professor at Rutgers University and the National University of Singapore. His research focuses on the discovery of new antibiotics for the treatment of TB and lung disease caused by Non-Tuberculous Mycobacteria (NTM). At CDI he established a fully enabled TB and NTM drug discovery platform for the discovery of target-lead couples and the delivery of preclinical development candidates. The platform includes mycobacterial strain collections, a range of in vitro potency assays, and in vivo (mouse) pharmacology and efficacy models. Target deconvolution and resistance analyses complement the lab’s compound profiling capabilities. With medicinal chemistry partners from industry and academia he developed a portfolio of de novo and repositioning drug discovery projects. Dr. Dick published over 150 papers in the field of discovery, mechanism of action & resistance of antibacterials with an h-index of 45.